In this episode, we host Nir Peles, Founder, BOD member and VP Business Development at Cannassure Therapeutics to discuss Cannassure’s cannabis-based pharma products.

Cannassure is currently developing innovative & standardized IP protected pharma products with the ‘look and feel’ of pharma products as opposed to plants. These products address topical delivery for skin indications such as psoriasis and rheumatism, fem-tech IUD targeting women’s health issues, and a standardized pill for delivering medical cannabis.

One of Israel’s leading cannabis producers, Cannassure produces medical-grade cannabis in a holistic integrated production system that includes an advanced indoor-aeroponic grow facility, a state-of-the-art extraction and processing facility, together with scientifically advanced R&D.

Nir welcomes strategic collaboration opportunities, contact him through his LinkedIn profile

Cannassure is publicly traded - TASE: CSURE,

Visit their website: http://cannassure.life/